# US 2026/0234248 A1 · Low dose antibody-based methods for treating hematologic malignancies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234248 A1
- Document ID: US20260234248A1
- Status: Published application
- Kind: A1
- Application number: 19/300,849
- Filed: 2025-08-15
- Published: 2026-08-13
- Earliest claimed: 2016-05-27
- Assignees: Actinium Pharmaceuticals, Inc.
- Applicants: Actinium Pharmaceuticals, Inc.
- Inventors: Dragan Cicic
- Web page: https://patentgrep.com/patent/US20260234248A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 51/1069: {the tumor cell being from blood cells, e.g. the cancer being a myeloma}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 35/02: specific for leukemia
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as 225Ac-HuM195.

## Claims

### Claim at position 1

-29. (canceled)

### Claim 30

A method for treating relapsed and/or refractory acute myeloid leukemia in a human subject, comprising the step of:
intravenously administering a therapeutically effective dose of lintuzumab labeled with an alpha particle-emitting isotope to a human subject afflicted with relapsed and/or refractory acute myeloid leukemia, wherein the human subject has a peripheral blast burden below 200 blast cells/μl.

### Claim 31 (depends on 30)

The method of claim 30, further comprising the step of before administering the labeled lintuzumab to the human subject, determining that the human subject has a peripheral blast burden below 200 blast cells/μl.

### Claim 32 (depends on 30)

The method of claim 30, wherein the human subject is ineligible to receive high intensity chemotherapy.

### Claim 33 (depends on 31)

The method of claim 31, wherein the human subject is ineligible to receive high intensity chemotherapy.

### Claim 34 (depends on 30)

The method of claim 30, further comprising the step of:
before administering the labeled lintuzumab to the human subject, administering low dose cytarabine to the human subject.

### Claim 35 (depends on 31)

The method of claim 31, further comprising the step of:
before administering the labeled lintuzumab to the human subject, administering low dose cytarabine to the human subject.

### Claim 36 (depends on 32)

The method of claim 32, further comprising the step of:
before administering the labeled lintuzumab to the human subject, administering low dose cytarabine to the human subject.

### Claim 37 (depends on 33)

The method of claim 33, further comprising the step of:
before administering the labeled lintuzumab to the human subject, administering low dose cytarabine to the human subject.

### Claim 38 (depends on 30)

The method of claim 30, wherein the human subject's peripheral blast burden is 50 blast cells/μl or lower.

### Claim 39 (depends on 30)

The method of claim 30, further comprising the step of:
before administering the labeled lintuzumab to the human subject, medically lowering the human subject's peripheral blast burden from at or above 200 blast cells/μl to below 200 blast cells/μl,
wherein the administering step is performed while the human subject's peripheral blast burden is still below 200 blast cells/μl.

### Claim 40 (depends on 39)

The method of claim 39, wherein the human subject's peripheral blast burden is medically lowered to 50 blast cells/μl or lower.

### Claim 41 (depends on 34)

The method of claim 34, further comprising the step of:
before administering the labeled lintuzumab to the human subject, medically lowering the human subject's peripheral blast burden from at or above 200 blast cells/μl to below 200 blast cells/μl,
wherein the administering step is performed while the human subject's peripheral blast burden is still below 200 blast cells/μl.

### Claim 42 (depends on 41)

The method of claim 41, wherein the human subject's peripheral blast burden is medically lowered to 50 blast cells/μl or lower.

### Claim 43

A method for treating acute myeloid leukemia in a human subject, comprising the step of:
intravenously administering a therapeutically effective dose of lintuzumab labeled with an alpha particle-emitting isotope to a human subject afflicted with acute myeloid leukemia, wherein the human subject has a peripheral blast burden below 200 blast cells/μl.

### Claim 44 (depends on 43)

The method of claim 43, further comprising the step of before administering the labeled lintuzumab to the human subject, determining that the human subject has a peripheral blast burden below 200 blast cells/μl.

### Claim 45 (depends on 43)

The method of claim 43, wherein the human subject is ineligible to receive high intensity chemotherapy.

### Claim 46 (depends on 44)

The method of claim 44, wherein the human subject is ineligible to receive high intensity chemotherapy.

### Claim 47 (depends on 43)

The method of claim 43, further comprising the step of:
before administering the labeled lintuzumab to the human subject, administering low dose cytarabine to the human subject.

### Claim 48 (depends on 44)

The method of claim 44, further comprising the step of:
before administering the labeled lintuzumab to the human subject, administering low dose cytarabine to the human subject.

### Claim 49 (depends on 45)

The method of claim 45, further comprising the step of:
before administering the labeled lintuzumab to the human subject, administering low dose cytarabine to the human subject.
